Alto Neuroscience (ANRO) Operating Expenses (2023 - 2026)

Alto Neuroscience has disclosed Operating Expenses across 4 years of filings, most recently posting $27.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $27.1 million, up 73.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.8 million (up 11.34% YoY), and the FY2025 annual result was $66.4 million, down 3.27% from the prior year.
• Operating Expenses came in at $27.1 million for Q1 2026 at Alto Neuroscience, up from $17.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $27.1 million in Q1 2026 to a low of $7.2 million in Q1 2023.
• The 4-year median for Operating Expenses is $15.7 million (2025), against an average of $15.4 million.
• Across the five-year window, Operating Expenses soared 101.0% in 2024 and decreased 20.84% in 2025, its largest moves.
• Alto Neuroscience's Operating Expenses stood at $11.8 million in 2023, then jumped by 44.47% to $17.0 million in 2024, then grew by 0.34% to $17.1 million in 2025, then jumped by 59.12% to $27.1 million in 2026.
• The last three Operating Expenses figures came in at $27.1 million (Q1 2026), $17.1 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.